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Purpose: To investigate the choroideremia (CHM) gene in two families with CHM and to characterize the related clinical
features.
Methods: Two families underwent complete ophthalmic examinations and three males were diagnosed with CHM.
Genomic DNA was extracted from the leukocytes of peripheral blood collected from the two families and from 100
unrelated control subjects from the same population. Exons 1–15 of CHM were amplified by PCR and directly sequenced.
Ophthalmic examinations included best-corrected visual acuity, slit-lamp examination, fundus examination, visual field,
optical coherence tomography, electroretinogram, and Pentacam.
Results: The affected men were hemizygous and had night blindness, chorioretinal atrophy spreading from the posterior
pole to the mid-periphery, and bareness of the sclera. A novel c.1488delGinsATAAC mutation was detected in CHM in
family 1. Another mutation c.1703 C>G (S558X) within exon 14 of CHM was identified in family 2, which caused the
serine 558 codon (TCA) to be changed to a stop codon (TGA).
Conclusions: This study identified a novel mutation in CHM associated with CHM and its related clinical features. Our
findings expand the genotypic spectrum of CHM mutations associated with CHM and confirm the role of Rab escort
protein-1 in the pathogenesis of CHM.
Choroideremia (CHM) has been recognized as clinically
distinct from other retinal degenerations for more than half a
century, and is known to be a genetic heterogeneous X-linked
recessive disease associated with different types of mutations
in the CHM gene (CHM) [1]. Affected males develop night
blindness in their teenage years, followed by loss of peripheral
vision because of the progressive visual field constriction, and
blindness. The incidence of CHM is estimated as 1 in 100,000
[1].
The CHM gene comprises 15 coding exons that span a
genomic sequence of approximately 186 kb, which is made
up of 653 amino acids and located on chromosome Xq21.2
[2]. It encodes Rab escort protein-1 (REP-1), which functions
in the prenylation of small Rab proteins in the eye. REPs can
bind to newly synthesized Rab protein to escort them to Rab
GGTases  [3,4].  They  contain  three  sequence-conserved
regions (SCR1, SCR2, and SCR3) that are similar in sequence
to  Rab  GDP-dissociation  inhibitor  proteins  [5,6].  Crystal
structure  analysis  of  REP  proteins  reveals  two  conserved
domains: a multisheet domain I and a smaller globular α-
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helical  domain  II  [5,6].  The  N-terminal  half  of  GDP-
dissociation  inhibitor  proteins  (the  first  450  amino  acids)
shares conserved regions (SCRs 1–3) with members of the
REP family. Some of the nonsense and frameshift mutations
have been observed in the C-terminal part in CHM patients
[5].
So  far,  more  than  100  different  pathogenic  CHM
mutations have been reported, most leading to a complete loss
of the gene product REP-1 [7,8]. The spectrum of defects
identified  in  CHM  of  patients  with  CHM  includes
translocations, deletions, and a variety of subtle mutations
[9-17].  Deletions  vary  in  extent  from  deletion  of  a  few
kilobases, to removal of several exons, to removal of the
complete CHM gene and virtually the entire Xq21 band [7,
10,16,18]. This study reports the mutational analysis of two
CHM families at the gene level and related clinical features,
and identifies two truncating mutations.
METHODS
Two families were diagnosed as having CHM (Figure 1) at
the  Zhongshan  Ophthalmic  Center.  We  performed  the
ophthalmic  examinations  as  follows:  Visual  acuity  was
examined using the ETDRS chart (Precision Vision, La Salle,
IL). Fundus photograph and fundus fluorescein angiography
imaging  was  performed  using  a  Heidelberg  Retina
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The  NIHON  KOHDEN  electroretinogram  (ERG)  system
(Neuropack, Tokyo, Japan) was used to assess the amplitudes
of  the  rod  and  cone  responses,  and  optical  coherence
tomography (OCT) scans (TOPCON, Tokyo, Japan) were
used to assess the thickness and pathology of the posterior pole
of the retina. Anterior segment measurements were measured
with  Pentacam  HR  version  70700  (Oculus,  Weltzar,
Germany).  In  addition,  physical  examinations  were
performed to exclude systemic diseases.
Sample  collection:  The  two  affected  families  were
identified at the Zhongshan Ophthalmic Center. One hundred
subjects without diagnostic features of CHM from the same
Figure 1. The pedigree of Chinese families with choroideremia.
Square symbols denote males, and circular symbols denote females.
The  shaded  symbols  indicate  ophthalmologist-confirmed
choroideremia  (CHM).  The  circles  with  a  dot  indicate  female
carriers. The arrow points to the proband. The transmission pattern
suggested that the CHM was inherited in an X-linked hereditary
manner. Panel A represents Family 1, panel B represents Family 2.
population were recruited to serve as normal controls. After
informed  consent  was  obtained  from  all  participating
individuals  following  the  principles  of  the  Declaration  of
Helsinki, venous blood samples were collected for genomic
DNA  extraction  from  peripheral  blood  leucocytes  using
standard protocols.
Mutation detection: All coding exons and their flanking
regions were amplified by PCR with the primers listed in
Table 1 [11]. The PCR products were sequenced from both
directions  with  the  ABI3730  Automated  Sequencer  (PE
Biosystems, Foster City, CA). The sequencing results were
analyzed using Chromas (version 2.3) and compared with the
reference sequences in the NCBI database.
RESULTS
Clinical data: The probands of family 1 and family 2 were
diagnosed as having bilateral CHM. Physical examinations
excluded  systemic  disorders  in  all  patients.  The  clinical
findings showed that the best-corrected visual acuity of the
proband (III-2) of family 1 was 0.3 OD (LogMAR) and 0.4
OS with myopia of −2.25D OD and −1.75D OS. Unlike the
normal homogeneous brown background of melanin pigment
in the normal retinal pigment epithelium (RPE) and choroid,
the  retina  of  the  proband  showed  symmetric  profound
chorioretinal atrophy with preservation of the central macula.
A fundus photograph (Figure 2A) of the right eye of the 38-
year-old  CHM-affected  proband  of  family  1  showed
symmetric  profound  chorioretinal  atrophy,  areas  of  RPE
disruption,  loss  of  choriocapillaris,  and  bare  sclera.
Fluorescein angiography of the same affected male patient
(Figure  2B)  showed  extensive  chorioretinal  atrophy  with
preservation of an island of RPE at the macular area.
Visual field examination showed only a central 5 degrees
of visual field (tunnel vision). OCT demonstrated that the
retina of the proband was thinner than normal and the signal
was  stronger  in  some  parts  of  the  retina  because  of  the
choriocapillaris atrophy and the bare sclera (Figure 3). ERG
showed no rod and cone responses according to the ERG
standards  of  the  International  Society  for  Clinical
Electrophysiology of Vision (ISCEV, 2008 Version) [19].
There  were  no  significant  differences  in  the  anterior
segment parameters between the affected patients and the
controls (p>0.05). The examination findings of the affected
men in family 2 were almost the same as those found in the
family 1 proband.
The mother (II-2) of the proband in family 1 had poor
visual acuity and visual field, whereas the older sister showed
good visual function in terms of both visual acuity and visual
field. Because the family lived some distance from Zhongshan
Ophthalmic Center, we were unable to obtain blood samples
from additional family members for mutation screening.
Mutation  screening:  Compared  to  the  unaffected  patients
(Figure 4A), sequencing of the complete coding region of
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hemizygous  mutation  c.1488delGinsATTAC  (Figure  4B).
This mutation is predicted to truncate the 653 amino acid
CHM protein by 157 amino acids. Sequencing of the complete
coding region of CHM in the affected member of family 2
showed a hemizygous mutation of a C to G transversion at
nucleotide 1703, changing the serine 558 codon (TCA; Figure
4C) to a stop codon (TGA; Figure 4D). The mutation c.1703
C>G  (S558X)  created  a  new  restriction  site  for  BsmAI,
permitting  convenient  DNA-based  diagnosis  among  the
family members. This alteration is expected to result in a
product that would lack the last 96 amino acids, predicting a
truncated  and  nonfunctional  REP-1.  These  were  the  only
changes seen in the affected men in the two families. The
alterations were not seen in 100 unrelated control subjects
(200  chromosomes)  from  the  same  population,  tested  by
bidirectional  sequence  analysis.  No  other  mutations  were
observed in the other exons.
DISCUSSION
In this study, we found two mutations in the two exons of
CHM that are associated with CHM: c.1488delGinsATAAC
and c.1703 C>G. These two mutations, rather than a rare
polymorphism in the normal population, are the causative
mutations in the two CHM families, respectively.
The novel c.1488delGinsATAAC mutation detected in
the CHM family 1 created a new premature stop codon that
indicates truncation of the C-terminal 157 residues of REP-1,
leaving only 496 amino acids of the 653 residules. So far,
nonsense, deletion, or insertion mutations have been detected
in CHM, and most of these will result in truncation of the
TABLE 1. PRIMERS USED FOR PCR.
Exon Forward (5′-3′) Reverse (5′-3′) Product size (bp)
1 GACCTTCCACCCAAGAACTAC ACAGTCTTCCTAAACTTTGTCC 216
2 TGTTCTATACAGCAATGGCA GGAAATATTAAATGCTATCGTT 190
3 TAAGGGTTAAAGATGGTTTGTTGATG TTTCTTCAGTGCAGGGTTACTATGTA 236
4 TTGCATGTTTCACACTGCCCAC AGTCATTAATTTAGTTTACCTGCAG 222
5.1 AGCCTGGTGTTTATTATTATATT GTCACTTCAGCACCATTTAC 246
5.2 GATCCAGAGAATGCGCTAG GCAAAGATGGGTAAAATTAGT 246
6 CCAATTTTTCTACTATTTCAAC AACTTAAGCTGATGCCCAGT 214
7 AGTTATATCATTAGGAAGCAG TTGGAGAGCACTACTTAATG 206
8 AGTTTAGTTCTGATTTTAAGTG CACTTTTAGAAGGGACAAGAA 309
9 TTTTCAACCCAATTACCCTA TATATATGAAGGTTACTTATATC 156
10 ATGAACTTTTATGGTATGCTTATCTT GTCAATAAAATTACCTTCGCTTGC 185
11 CGAAACTTATCCATGGAATC GTGTAGTGATTAGTTCACCA 207
12 GATCTAACAGCTGTGTCTGAT AAAATACAAATAACCACTCT 174
13 GCTCAGCTCTCTATTATCCAT GAAGATTATGATGGTTACAT 258
14 TAGGCTACACAGTGTAGTAA GACTTCTCTCCTCCCAGAGG 322
15 AGTTAATGCCAGAAATGCAC GGGTATCCAGTTTGGTGTATA 289
               Summary of the primers and products length used for the amplification of the all exons of CHM.
Figure 2. Fundus photographs of the right eye of the 38-year-old choroideremia-affected proband of family 1 show symmetric profound
chorioretinal atrophy with preservation of the central macula. A: The fundus shows areas of retinal pigment epithelium (RPE) disruption,
severe chorioretinal atrophy, loss of choriocapillaris, and bare sclera. B: Fluorescein angiography of the same affected male patient shows
extensive chorioretinal atrophy with preservation of an island of RPE at the macular area.
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reported previously.
Figure 4. DNA sequence of a part of the CHM gene in the unaffected
men  and  affected  individuals.  A  represents  normal  sequence.  B
represents  a  hemizygous  mutation  1488delGinsATTAC  in  the
affected man. This mutation is predicted to truncate the 653 amino
acid choroideremia (CHM) protein by 157 amino acids because of
the insertion of the stop codon TAA. C represents normal sequence.
D represents a C to G transversion at nucleotide 1703.
Our data demonstrating the truncation in the CHM gene
from CHM patients suggest that a REP-1 protein lacking only
157 amino acids at the carboxy terminus is unable to function
as a subunit of Rab GG transferase in vivo. It is likely that this
abnormal REP-1 is degraded by enzymatically.
The mutation c.1703 C>G (S558X) within exon 14 of the
CHM  gene,  which  was  found  in  CHM  family  2,  was
previously described in one family in southern France [20].
Direct DNA sequencing revealed a C to G transversion at
nucleotide 1703, changing the serine 558 codon (TCA) to a
stop codon (TGA). Mutation c.1703 C>G (S558X) creates a
new restriction site for BsmAI, permitting convenient DNA-
based diagnosis in the family. This alteration is expected to
result in a product that would lack the last 96 amino acids,
predicting a truncated and nonfunctional REP-1. The c.1703
C>G  (S558X)  mutation  occurring  in  one  of  the  Chinese
families in our study was also reported in a French family,
which  might  indicate  that  the  nucleotide  1703  is  easily
damaged.
In this study, we performed a detailed investigation of the
clinical features of CHM. Affected males in the two families
of this study all developed night blindness in their teenage
years, followed by loss of peripheral vision due to progressive
visual field constriction and blindness. Moreover, affected
patients in both families all had various grades of myopia.
Most  previous  studies  did  not  provide  the  details  of  the
refractive  errors  of  the  patients,  but  Binkhorst  reported  a
patient with CHM who also had myopia [21]. We speculate
that there is a close relationship between myopia and CHM.
The defect in the choroid and the fragility of the blood-
retina barrier, as observed on OCT in our patients, make the
Figure 3. Optical coherence tomography shows the retina of the proband to be thinner than normal; the signal was stronger in the some parts
of the retina because of the choriocapillaris atrophy and the bare sclera (arrow).
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Krock and coauthors [22] have documented that mutations in
Rep1 disrupt cellular processes in the RPE, and these cause
photoreceptor death. Patients with CHM have been reported
as  having  cataract  [21],  cystic  macular  edema  [23],  and
recurrent uveitis [24].
CHM is a rare eye disease with clinical features similar
to those of RP. So far, no effective treatment exists for either
disease.  Transplantation  of  autologous  transduced  iris
pigment epithelial (IPE) cells into the subretinal space might
help  CHM  patients  in  the  future  [25].  In  animal  studies,
several neurotrophic factor genes have been transduced into
IPE  cells  with  adeno-associated  virus,  plasmid  vector,  or
adenovirus, and the transplantation of those transduced IPE
cells may help rescue photoreceptor cells from several types
of photoreceptor damage in animals [25].
In summary, we identified two families with CHM of
which  the  affected  men  were  hemizygous  and  had  night
blindness, chorioretinal atrophy spreading from the posterior
pole to the mid-periphery, and bareness of the sclera. Two
truncating mutations were found in these two families, each
with one distinct mutation. One was a novel mutation not
previously reported: c.1488delGinsATAAC.
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